Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Gastric adenocarcinoma with

Supriatna Y, Kishimoto T, Uno T, et al. Evidence for hepatocellular differentiation in alpha-fetoprotein-negative gastric adenocarcinoma with hepatoid morphology a study with in situ hybridisation for albumin mRNA. Pathology. 2005 37 211-215. [Pg.590]

Fielding J, Scholefield J, Stuart R, Hawkins R, McCulloch P, Maughan T, et al. A randomized doubleblind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc Am Soc Clin Oncol 2000 19 240a (abstract). [Pg.390]

Immunohistochemical staining of tonsillitis, gastric adenocarcinomas, and breast carcinomas can be obtained using MIB-1 antibody in conjunction with EDTA-NAOH solution and a pressure cooker (Kim et ah, 1999b). EDTA solution is thought to be more effective than other buffers in unmasking the epitopes, presumably because it removes (chelates) tissue-bound calcium ions. [Pg.191]

Bioenergetic dysfunction of mitochondria has been reported as a hallmark of many types of cancers (i.e., downregulation of ATP synthase /3-subunit expression in liver, kidney, colon, squamous esophageal, and lung carcinomas, as well as in breast and gastric adenocarcinomas). ATP synthase d-subunit was found to be associated with chemoresistance to 5-fluorouracil (5-FU) in CRC using 2D-PAGE. In a functional assay, suppressed ATP synthase d-subunit expression by siRNA transfection increased cell viability in the presence of 5-FU [115]. [Pg.126]

A 55-year-old man with gastric adenocarcinoma received fluorouracil 1 g intravenously each week for 9 weeks and mitomycin 10 mg intravenously every 3 weeks (46). After 12 treatments he developed severe dyspnea. [Pg.1409]

Chen HC, Chu RY, Hsu PN, et al. Loss of Egastric adenocarcinomas. Cancer Lett. 2003 201 97-106. [Pg.540]

Ajani, J.A., Kelsen, D.P., Haller, D., Hargraves, K., Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxombicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J. 2000, 6, 78-81. [Pg.1185]

See other pages where Gastric adenocarcinoma with is mentioned: [Pg.2417]    [Pg.509]    [Pg.523]    [Pg.491]    [Pg.2417]    [Pg.509]    [Pg.523]    [Pg.491]    [Pg.336]    [Pg.121]    [Pg.180]    [Pg.482]    [Pg.489]    [Pg.254]    [Pg.222]    [Pg.172]    [Pg.162]    [Pg.1316]    [Pg.1481]    [Pg.90]    [Pg.33]    [Pg.298]    [Pg.2866]    [Pg.861]    [Pg.6]    [Pg.763]    [Pg.636]    [Pg.642]    [Pg.65]    [Pg.505]    [Pg.507]    [Pg.507]    [Pg.508]    [Pg.508]    [Pg.509]    [Pg.509]    [Pg.509]    [Pg.511]    [Pg.519]    [Pg.540]    [Pg.122]    [Pg.123]    [Pg.630]    [Pg.242]    [Pg.328]    [Pg.178]   


SEARCH



Adenocarcinoma

© 2024 chempedia.info